

Supplemental Information

First-in-Human Intravenous Seprehvir in Young

Cancer Patients: A Phase 1 Clinical Trial

Keri A. Streby, Mark A. Currier, Melinda Triplet, Kristy Ott, Devon J. Dishman, Michele R. Vaughan, Mark A. Ranalli, Bhuvana Setty, Micah A. Skeens, Stacy Whiteside, Nicholas D. Yeager, Kellie B. Haworth, Kathleen Simpson, Joe Conner, and Timothy P. Cripe

Supplemental Table 1. Dose administered based on post-injection titers.

Patient	Assay Date	Titer (plaque forming units)
HSV 01	2/7/14	2600000
HSV 02	10/9/14	24000*
HSV 03	6/1/15	1500000
HSV 04	4/21/16	2400000
HSV 05	8/11/16	1400000
HSV 06	9/21/16	1500000
HSV 06- EAU	11/3/16	2800000
HSV 06- EAU	11/10/16	1800000
HSV 07	2/10/17	7000000
HSV 08	7/25/17	3400000**
HSV 09	1/17/18	3700000

Supplemental Table 1. Clinical vial titers were determined by the tissue culture inhibitor dose-50 quantal method expressed as infectious units (iu) whereas post-injection titers were determined by direct quantitative plaque formation method expressed as plaque forming units (pfu). 1 iu = 1 pfu. * = freeze-thawed after storage in lactate ringer solution; ** = freeze-thawed after storage in 10% glycerol